$12.48
+0.81%Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Chief Financial Officer
Compensation
$569,695
Chief Medical Officer & Head of Development
Chief Science Officer
Compensation
$565,024
General Counsel & Corporate Secretary
Compensation
$612,780
President, Chief Executive Officer & Director
Compensation
$1,093,893
Senior Director of Investor Relations & Corporate Communications
Senior Manager of Accounting
Senior Vice President & Head of Research
Senior Vice President of Clinical Operations
Vice President of Human Resources
During the last 12 months, insiders have purchased $414K and sold $753K worth of CTNM shares, resulting in $339K of net selling activity.
0
0.00
12.2K
161.42K
-161K
-$161K
0
0.00
41.2K
591.55K
-592K
-$592K
0
0.00
0
0.00
+0
+$0
103.3K
414.03K
0
0.00
+414K
+$414K
Boyce Sarah
Director
$59K
Brady Todd R.
Director
$59K
Ignelzi Troy A.
Director
$59K
Lyons-Williams Lori
Director
$59K
Ware Olivia C
Director
$59K
Lorrain Daniel S.
Officer: Chief Scientific Officer
$496K
Watkins Tim
Officer: Cmo & Head Of Development
$137K
Stengone Carmine N.
Director, Officer: Ceo And President
$120K
Slightly bearish with $339K net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
5 insider buyers vs. 3 sellers. More insiders buying than selling indicates positive sentiment.
CTNM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 26, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 26, 2025 | 2025 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.